Abstract:During the transplant process, the graft is exposed to numerous events, which may enhance its immunogenicity. In particular, factors related to brain death, such as hemodynamic instability and systemic release of cytokines, cold preservation on harvesting, and reperfusion injury, are known to accumulate in harm, conveying a proinflammatory state to the graft before transplant. Alloimmune reactivity is initiated when the host immune system detects non-self-antigens in the context of "danger signals." Eliminating these danger signals by modifying the graft before transplant has the potential to attenuate the alloimmune response. The molecules, which mediate danger signals, have not yet been fully identified. Free oxygen radicals and interferon-gamma are important candidates. One of the most important protective mechanisms against oxidative stress is the heme oxygenase 1 system. Up-regulation of heme oxygenase 1 in grafts has been shown to prevent ischemia-reperfusion damage and improve long-term graft survival in various transplant models. The benefit of blocking the action of interferon-gamma in kidney transplants is less clear because the compound plays such a complex and pivotal role in the immune response, and experimental data with interferon-gamma receptor knockout mice are conflicting. It has recently become clear that catecholamines are important graft-modifying agents. Dopamine is capable of stimulating the induction of protective enzymes like heme oxygenase-1 (HO-1) rendering the organ more resistant to the insult of ischemia/reperfusion and inflammation. Retrospective clinical data suggest that treatment of brain-dead organ donors with catecholamines is associated with less rejection and a better long-term graft survival of kidneys transplanted from these donors. Catecholamines can also modulate cytokine production and prevent cold-induced damage. Other substances, such as proteoglycans and phosphatidylethanolamine-bound hyaluronic acid, may interfere with the actions of interferon-gamma. Further studies of these compounds in experimental animal models and in prospective randomized clinical trials will help establish their efficacy in donor pretreatment. It is important to underscore that donor pretreatment will have great advantages for the recipient because an improved long-term graft survival could thus be achieved cost-efficiently and without great effort or side effects.

Trained immunity in organ transplantation

Impact of Regulatory T Cells on Innate Immune Cells in a Pre-Sensitized Heart Transplant Model

Innate immunity: Trained immunity and innate allorecognition against the allograft

Targeting Macrophages in Organ Transplantation: A Step Toward Personalized Medicine

Activation of immune signals during organ transplantation

Innate immune modulation in transplantation: mechanisms, challenges, and opportunities

New strategies in immune tolerance induction

Advances in Transplantation Tolerance

Tolerogenic dendritic cells in organ transplantation

The Evolving Roles of Macrophages in Organ Transplantation

Intragraft regulatory T cells in the modern era: what can high-dimensional methods tell us about pathways to allograft acceptance?

Transplantation tolerance and its outcome during infections and inflammation

T Regulatory Cells As an Immunotherapy for Transplantation

Graft-Specific Regulatory T Cells for Long-Lasting, Local Tolerance Induction

Tissue-Resident Macrophages in Solid Organ Transplantation: Harmful or Protective?

Innate and Adaptive Immune Responses in Intestinal Transplant Rejection: Through the Lens of Inflammatory Bowel and Intestinal Graft-Versus-Host Diseases

Veto cells in transplantation tolerance 1

T regulatory cells as an immunotherapy for transplantation.

Transplantation tolerance

Preconditioning strategies to limit graft immunogenicity and cold ischemic organ injury

The Dual Regulatory Roles of Macrophages in Acute Allogeneic Organ Graft Rejection